



Study	Intervention	Controls	Odds ratio	95% CI	z	P
Arabi et al. 2009	13/25	36/66	0.903	0.359 to 2.270		
Basil et al. 2000	61/70	115/159	2.593	1.187 to 5.665		
Black et al. 2006	77/93	222/380	3.425	1.926 to 6.092		
Nagle et al. 2018	141/163	499/565	0.848	0.505 to 1.422		
Ruiz et al. 2014	50/64	113/148	1.106	0.547 to 2.236		
Talhok et al. 2016	9/12	22/38	2.182	0.508 to 9.364		
Total (fixed effects)	351/427	1007/1356	1.615	1.218 to 2.142	3.331	0.00
Total (random effects)	351/427	1007/1356	1.565	0.894 to 2.740	1.568	0.11
Q	16.723					
DF	5					
Significance level	P = 0.005					
I <sup>2</sup> (inconsistency)	70.10%					

(A)



Study	Intervention	Controls	Odds ratio	95% CI	z	P
Arabi et al. 2009	12/25	30/66	1.108	0.440 to 2.786		
Basil et al. 2000	9/70	44/159	0.386	0.177 to 0.842		
Black et al. 2006	16/93	81/380	0.767	0.424 to 1.386		
Nagle et al. 2018	22/134	66/565	1.485	0.879 to 2.509		
Ruiz et al. 2014	10/60	25/138	0.904	0.404 to 2.023		
Talhok et al. 2016	3/12	4/38	2.833	0.535 to 15.015		
Total (fixed effects)	72/394	250/1346	0.915	0.681 to 1.229	-0.589	0.556
Total (random effects)	72/394	250/1346	0.936	0.593 to 1.478	-0.282	0.778
Q	10.248					
DF	5					
Significance level	P = 0.068					
I <sup>2</sup> (inconsistency)	51.21%					
95% CI for I <sup>2</sup>	0.00 to 80.58					

(B)



**Supplementary Fig. S8.** Pooled odd ratio of International Federation of Gynecology and Obstetrics stage in mismatch repair (MMR) deficiency in endometrial carcinoma (EC) vs. proficient MMR EC [4,6,13,14,21,24]: (A) stage I–II and (B) stage III–IV. CI, confidence interval.